Ann E Clarke1, Jinoos Yazdany2, Shaum M Kabadi3, Emily Durden4, Isabelle Winer5, Kirstin Griffing3, Karen H Costenbader6. 1. Division of Rheumatology, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada. Electronic address: aeclarke@ucalgary.ca. 2. University of California - San Francisco, San Francisco, CA, USA. 3. AstraZeneca, Gaithersburg, MD, USA. 4. Headspace, Santa Monica, CA, USA. 5. IBM Watson Health, Ann Arbor, MI, USA. 6. Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Abstract
OBJECTIVE: To estimate the economic burden of systematic lupus erythematous (SLE), stratified by disease severity, in commercially- and Medicaid-insured US populations. METHODS: Adults (≥18 years) with SLE treated with antimalarials, selected biologics, immunosuppressants, and systemic glucocorticoids (2010-2014) were identified within the commercial and Medicaid insurance IBM MarketScan® databases (index date = first SLE medication claim). Both cohorts were stratified into mild (receiving antimalarial or glucocorticoid monotherapy ≤5 mg/day) versus moderate/severe SLE (receiving glucocorticoids >5 mg/day, biologic, immunosuppressant, or combination therapy) during a 6-month exposure period. All-cause healthcare utilization and costs were evaluated during the 12 months following the exposure period. RESULTS: Among 8231 commercially-insured patients, 32.6% had mild and 67.4% had moderate/severe SLE by our definition. Among 802 Medicaid-insured patients, 25.2% had mild and 74.8% had moderate/severe SLE. Adjusted mean total healthcare costs, excluding pharmacy, for moderate/severe SLE patients were higher than for mild SLE patients in the commercially-insured ($39,021 versus $23,519; p < 0.0001) and Medicaid-insured populations ($56,050 versus $44,932; p = 0.06). In both SLE severity populations total unadjusted costs were significantly higher among Medicaid-insured than commercially-insured patients. CONCLUSION: Commercially-insured patients with treatment suggesting moderate/severe SLE incurred significantly higher adjusted mean healthcare costs, excluding pharmacy, compared with mild SLE patients. While not reaching statistical significance, moderate/severe Medicaid-insured patients had higher costs then mild SLE patients. Total unadjusted healthcare costs were significantly higher among Medicaid-insured than commercially-insured patients. These differential costs are important to consider and monitor when implementing interventions to improve health and reduce healthcare spending for SLE.
OBJECTIVE: To estimate the economic burden of systematic lupus erythematous (SLE), stratified by disease severity, in commercially- and Medicaid-insured US populations. METHODS: Adults (≥18 years) with SLE treated with antimalarials, selected biologics, immunosuppressants, and systemic glucocorticoids (2010-2014) were identified within the commercial and Medicaid insurance IBM MarketScan® databases (index date = first SLE medication claim). Both cohorts were stratified into mild (receiving antimalarial or glucocorticoid monotherapy ≤5 mg/day) versus moderate/severe SLE (receiving glucocorticoids >5 mg/day, biologic, immunosuppressant, or combination therapy) during a 6-month exposure period. All-cause healthcare utilization and costs were evaluated during the 12 months following the exposure period. RESULTS: Among 8231 commercially-insured patients, 32.6% had mild and 67.4% had moderate/severe SLE by our definition. Among 802 Medicaid-insured patients, 25.2% had mild and 74.8% had moderate/severe SLE. Adjusted mean total healthcare costs, excluding pharmacy, for moderate/severe SLEpatients were higher than for mild SLEpatients in the commercially-insured ($39,021 versus $23,519; p < 0.0001) and Medicaid-insured populations ($56,050 versus $44,932; p = 0.06). In both SLE severity populations total unadjusted costs were significantly higher among Medicaid-insured than commercially-insured patients. CONCLUSION: Commercially-insured patients with treatment suggesting moderate/severe SLE incurred significantly higher adjusted mean healthcare costs, excluding pharmacy, compared with mild SLEpatients. While not reaching statistical significance, moderate/severe Medicaid-insured patients had higher costs then mild SLEpatients. Total unadjusted healthcare costs were significantly higher among Medicaid-insured than commercially-insured patients. These differential costs are important to consider and monitor when implementing interventions to improve health and reduce healthcare spending for SLE.
Authors: Bevra H Hahn; Maureen A McMahon; Alan Wilkinson; W Dean Wallace; David I Daikh; John D Fitzgerald; George A Karpouzas; Joan T Merrill; Daniel J Wallace; Jinoos Yazdany; Rosalind Ramsey-Goldman; Karandeep Singh; Mazdak Khalighi; Soo-In Choi; Maneesh Gogia; Suzanne Kafaja; Mohammad Kamgar; Christine Lau; William J Martin; Sefali Parikh; Justin Peng; Anjay Rastogi; Weiling Chen; Jennifer M Grossman Journal: Arthritis Care Res (Hoboken) Date: 2012-06 Impact factor: 4.794
Authors: Tzu-Chieh Lin; Michael F Marmor; Medha Barbhaiya; Hongshu Guan; Sarah K Chen; Candace H Feldman; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2018-11 Impact factor: 4.794
Authors: Candace H Feldman; Jinoos Yazdany; Hongshu Guan; Daniel H Solomon; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2015-12 Impact factor: 4.794
Authors: Candace H Feldman; Linda T Hiraki; Jun Liu; Michael A Fischer; Daniel H Solomon; Graciela S Alarcón; Wolfgang C Winkelmayer; Karen H Costenbader Journal: Arthritis Rheum Date: 2013-03
Authors: Peter M Izmirly; Isabella Wan; Sara Sahl; Jill P Buyon; H Michael Belmont; Jane E Salmon; Anca Askanase; Joan M Bathon; Laura Geraldino-Pardilla; Yousaf Ali; Ellen M Ginzler; Chaim Putterman; Caroline Gordon; Charles G Helmick; Hilary Parton Journal: Arthritis Rheumatol Date: 2017-09-10 Impact factor: 10.995
Authors: Sarah K Chen; Medha Barbhaiya; Michael A Fischer; Hongshu Guan; Tzu-Chieh Lin; Candace H Feldman; Brendan M Everett; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2019-01 Impact factor: 4.794
Authors: Fruzsina Kósa; Péter Kunovszki; Judit Gimesi-Országh; Melinda Kedves; Melinda Szabó; Chetan S Karyekar; György Nagy Journal: Arthritis Res Ther Date: 2022-05-19 Impact factor: 5.606
Authors: Andreas Schwarting; Heiko Friedel; Elena Garal-Pantaler; Marc Pignot; Xia Wang; Henk Nab; Barnabas Desta; Edward R Hammond Journal: Rheumatol Ther Date: 2021-02-05